Tiotropium in the management of paediatric and adolescent asthma: Systematic review

Meera Sunther; Keisha Marchon; Atul Gupta

doi:10.1016/j.prrv.2020.08.003

Tiotropium in the management of paediatric and adolescent asthma: Systematic review

Paediatr Respir Rev. 2021 Jun:38:58-62. doi: 10.1016/j.prrv.2020.08.003. Epub 2020 Aug 25.

Authors

Meera Sunther¹, Keisha Marchon¹, Atul Gupta²

Affiliations

¹ Department of Respiratory Paediatrics, King's College Hospital, London, UK.
² Department of Respiratory Paediatrics, King's College Hospital, London, UK; Institute for Women's and Children's Health, King's College London, London, UK. Electronic address: atul.gupta@kcl.ac.uk.

PMID: 33243704
DOI: 10.1016/j.prrv.2020.08.003

Abstract

Tiotropium bromide is a long-acting muscarinic antagonist (LAMA) and is the only LAMA licensed for management for patients' ≥6 years old with severe asthma who have experienced one or more severe asthma exacerbations in the preceding year. Recent clinical trials have demonstrated that once-daily tiotropium is safe and efficacious in 6-17 year-olds with symptomatic asthma despite treatment with inhaled corticosteroids (ICSs), with or without additional controllers. In this paper, we review the evidence of the safety and efficacy of tiotropium add-on maintenance treatment in children and adolescents with symptomatic moderate and severe asthma.

Keywords: Asthma; Children; Efficacy; Safety; Tiotropium.

Publication types

Review
Systematic Review

MeSH terms

Administration, Inhalation
Adolescent
Adrenal Cortex Hormones / therapeutic use
Asthma* / drug therapy
Bronchodilator Agents / therapeutic use
Child
Humans
Muscarinic Antagonists / therapeutic use
Tiotropium Bromide / therapeutic use

Substances

Adrenal Cortex Hormones
Bronchodilator Agents
Muscarinic Antagonists
Tiotropium Bromide